TLDR
- Shares of Novo Nordisk gained more than 3% following FDA enforcement action targeting 30 telehealth providers for deceptive GLP-1 drug marketing.
- Telehealth providers incorrectly marketed compounded versions of semaglutide and tirzepatide as “generic” alternatives to Wegovy and Zepbound.
- This marks the FDA’s second enforcement wave, continuing a crackdown initiated in September under directives from the Trump administration.
- Recipients of the warning letters must submit written responses within 15 working days detailing corrective measures.
- Citi Research highlighted the heightened significance of these letters, noting the FDA’s prior DOJ referral of Hims & Hers.
Shares of Novo Nordisk surged over 3% Wednesday following the FDA’s issuance of warning letters to 30 telehealth providers accused of making deceptive claims regarding compounded GLP-1 medications.
The enforcement action focused on providers that marketed compounded semaglutide and tirzepatide formulations using misleading terms such as “generic Zepbound” or “generic Mounjaro.” These are proprietary brand names for Eli Lilly’s tirzepatide medications.
Certain providers also marketed these compounds under proprietary trademarks while failing to identify themselves as the compounding entity. According to the FDA, this practice created the false impression that these firms were the original manufacturers.
The regulatory agency emphasized a critical distinction: compounded medications lack FDA approval and cannot be equated with generic pharmaceutical products.
“Compounded drugs can be important for overcoming shortages or meeting unique patient needs — but compounders should not try to compound drugs in a way that circumvents FDA’s approval process,” FDA Commissioner Marty Makary said in a statement.
Semaglutide serves as the primary active component in Novo Nordisk’s Wegovy and Ozempic products. Tirzepatide functions as the key ingredient in Eli Lilly’s Zepbound and Mounjaro treatments. A limited number of providers also received citations for deceptive marketing of liraglutide, which Novo Nordisk markets as Saxenda.
Second Round of FDA Action
This enforcement wave represents the second round of warning letters since the FDA initiated its compliance campaign in September. The initial wave included notices sent to companies such as Eli Lilly, Novo Nordisk, and telehealth provider Hims & Hers Health.
The present enforcement action follows President Trump’s executive directive calling for stricter oversight of direct-to-consumer pharmaceutical marketing. The FDA reports issuing thousands of such warning letters during the past six months — exceeding the total issued throughout the entire previous decade.
Recipients of warning letters face a 15-working-day deadline to submit written responses detailing their compliance plans.
Hims & Hers has emerged as a recurring target in this regulatory campaign. The FDA issued a February warning regarding potential enforcement over the company’s $49 compounded weight-loss medication. Novo Nordisk subsequently filed a lawsuit against the company during the same month.
The FDA also forwarded Hims & Hers to the Department of Justice in early February.
What Analysts Are Saying
Citi Research characterized the latest warning letters as particularly significant given the intensifying regulatory landscape.
The investment firm referenced the DOJ referral as evidence that non-compliant providers may face more severe penalties.
Citi Research also observed that Commissioner Makary has separately indicated plans to impose restrictions on active pharmaceutical ingredients utilized in compounded GLP-1 formulations. Such regulatory action would further constrain the compounding market.
The timing increases pressure as expanded Medicare coverage for GLP-1 medications approaches in the second quarter.
Novo Nordisk shares closed Wednesday’s trading session up 3.59%.
